TScan Therapeutics announces 2023 clinical plans, milestones

TScan Therapeutics announced its 2023 clinical pipeline plans and highlighted recent corporate achievements. "We made significant progress and growth in 2022, positioning both our solid tumor and hematologic malignancies programs for important data readouts in 2023," said David P. Southwell, President and Chief Executive Officer. "Our solid cash runway funds us well into 2024, seeing us through to multiple value-generating milestones. We believe that 2023 will be a pivotal year for TScan as we continue to advance our industry-leading clinical stage portfolio of TCR-T therapy candidates in both our solid tumor and hematologic malignancies programs." Clinical Plans and Expected Milestones: In the hematologic malignancies program, the Company expects to enroll the first two cohorts in the Phase 1 umbrella trial for TSC-100 and TSC-101 in the first half of 2023 and to report top-line data by the end of 2023. Additionally, the Company expects to share prevention of relapse data in 2024. In the solid tumor program, the Company plans to file INDs for HPV and PRAME in the first half of 2023 with two additional INDs to be filed by the end of 2023; expects preliminary clinical data for the most advanced TCRs by the end of 2023. The Company expects to report initial multiplex therapy data for this program in 2024